Abstracts Archive - Page 929 of 2425 - ACR Meeting Abstracts

Abstract Number: 2560 • 2019 ACR/ARP Annual Meeting
Factors Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus Patients with End Stage Renal Disease
Maria Salgado Guerrero¹, Alejandra Londono Jimenez ², Chrisanna Dobrowolsky ², Shudan Wang ², Wenzhu B. Mowrey ³ and Anna Broder ², ¹Internal Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Hydroxychloroquine (HCQ) use in SLE has been associated with a lower risk of end-organ damage, SLE flares, and thrombosis1,2. However the benefits of HCQ…
Abstract Number: 2561 • 2019 ACR/ARP Annual Meeting
Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells
Jun Kikuchi¹, Hironari Hanaoka ¹, Shuntaro Saito ¹, Tatsuhiro Oshige ¹, Kazuoto Hiramoto ¹, Yuko Kaneko ¹, Noriyasu Seki ², Hideto Tsujimoto ² and Tsutomu Takeuchi ¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Mitsubishi Tanabe Pharma Corporation Sohyaku. Innovative Research Division, Toda-shi, Saitama, Japan
Background/Purpose: chievement of renal remission has been the target of the induction therapy in patients with active lupus nephritis (LN). Deep remission (DR) defined as…
Abstract Number: 2562 • 2019 ACR/ARP Annual Meeting
Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus – Meta-analyses of Observational Studies Published Between 1979 and 2018
Anselm Mak¹, Mike W.L.- Cheung ¹, Wai Yee Joanna Leong ², Bhushan Dharmadhikari ³, Nien Yee Kow ³, Michelle Petri ⁴, Susan Manzi ⁵, Ann Clarke ⁶, Cynthia Aranow ⁷, Laurent Arnaud ⁸, Anca Askanase ⁹, Sang-Cheol Bae ¹⁰, Sasha Bernatsky ¹¹, Ian Bruce ¹², Jill Buyon ¹³, W. Winn Chatham ¹⁴, Nathalie Costedoat-Chalumeau ¹⁵, MA Dooley ¹⁶, Paul Fortin ¹⁷, Ellen M Ginzler ¹⁸, Dafna Gladman ¹⁹, Caroline Gordon ²⁰, John G Hanly ²¹, Murat Inanc ²², David A Isenberg ²³, Soren Jacobsen ²⁴, Judith James ²⁵, Andreas Jönsen ²⁶, Kenneth C Kalunian ²⁷, Diane Kamen ²⁸, S Sam Lim ²⁹, Eric Morand ³⁰, Christine Peschken ³¹, Bernardo A. Pons-Estel ³², Anisur Rahman ³³, Rosalind Ramsey-Goldman ³⁴, Juanita Romero-Diaz ³⁵, Guillermo Ruiz-Irastorza ³⁶, Jorge Sanchez-Guerrero ³⁷, Kristjan Steinsson ³⁸, Elisabet Svenungsson ³⁹, Murray Urowitz ⁴⁰, Ronald van Vollenhoven ⁴¹, Evelyne Vinet ⁴², Alexandre Voskuyl ⁴³, Daniel J Wallace ⁴⁴ and Graciela Alarcón ⁴⁵, ¹National University of Singapore, Singapore, Singapore, ²Changi General Hospital, Singapore, Singapore, ³National University of Singapore, Singapore, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Allegheny Health Network, Pittsburg, PA, ⁶University of Calgary, Calgary, AB, Canada, ⁷Feinstein Institute for Medical Research, Manhasset, NY, ⁸Service de Rhumatologie, Centre National de Référence des Maladies Autoimmunes Systemiques Rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, ⁹Columbia University Medical Center, New York, NY, ¹⁰Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹²University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ¹³NYU School of Medicine, New York, ¹⁴University of Alabama Medical Center, Birmingham, AL, ¹⁵Cochin University Hospital, Paris, France, ¹⁶UnC Kidney Centre, Chapel Hill, NC, ¹⁷Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹⁸State University of New York Downstate Medical Center, Brooklyn, NY, ¹⁹Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ²⁰University of Birmingham, Birmingham, United Kingdom, ²¹Dalhousie University, Halifax, NS, Canada, ²²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²³Centre for Rheumatology, London, United Kingdom, ²⁴Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ²⁵Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁶Lund University, Lund, Sweden, ²⁷UC San Diego School of Medicine, LaJolla, CA, ²⁸Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ²⁹Emory University, Atlanta, GA, ³⁰Monash University, Melbourne, Victoria, Australia, ³¹University of Manitoba, Winnipeg, Canada, ³²Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR), Grupo Oroño, Rosario, Rosario, Argentina, ³³University College London, London, United Kingdom, ³⁴Northwestern University, Chicago, IL, ³⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ³⁶Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, Barakaldo, Spain, ³⁷Toronto Western Hospital, Toronto, ON, Canada, ³⁸Landspitali, University Hospital, Reykjavik, Iceland, ³⁹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ⁴⁰University Health Network, University of Toronto, Toronto, ON, Canada, ⁴¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴²McGill University Health Centre, Montreal, QC, Canada, ⁴³Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁴⁴Cedars-Sinai Medical Centre, Beverly Hills, CA, ⁴⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: The impact of glucocorticoid (GC) use on major organ damage in SLE patients has not been formally studied by amalgamating the relevant data published…
Abstract Number: 2563 • 2019 ACR/ARP Annual Meeting
PK/PD, Safety and Exploratory Efficacy of Subcutaneous Anifrolumab in SLE: A Phase-II Study in Interferon Type I High Patients with Active Skin Disease
Ian Bruce¹, Alireza Nami ², Erik Schwetje ³, M Edward Pierson ⁴, Yen Lin Chia ⁵, Denison Kuruvilla ⁵, Gabriel Abreu ⁶, Raj Tummala ³ and Catharina Lindholm ⁶, ¹University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ²Joint & Muscle Medical Care, Charlotte, NC, US, Charlotte, NC, ³AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD, ⁴AstraZeneca, Gaithersburg, MD, US, Gaithersburg, MD, ⁵AstraZeneca, South San Francisco, CA, US, South San Francisco, CA, ⁶AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Anifrolumab, a fully human anti–IFN Type I receptor mAb, is under investigation for the treatment of SLE at a dose of 300 mg intravenously…
Abstract Number: 2564 • 2019 ACR/ARP Annual Meeting
Adherence to Hydroxychloroquine Influences the Incidence of Organ Damage During Follow-up in Patients with Systemic Lupus Erythematosus
Ji-Hyoun Kang¹, Seong-Eun Choi ¹, Haimuzi Xu ¹, Dong-Jin Park ¹ and Shin-Seok Lee ², ¹Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea, ²Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone drug in patients with systemic lupus erythematosus (SLE), decreasing the risk of flares and comorbidities and improving survival. This…
Abstract Number: 2565 • 2019 ACR/ARP Annual Meeting
Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus
Richard Dimelow ¹, Beulah Ji² and Herbert Struemper ³, ¹GSK, Stevenage, United Kingdom, ²GSK, Uxbridge, Middlesex, United Kingdom, ³GSK, Research Triangle Park
Background/Purpose: Belimumab is approved in adults with active SLE and for childhood-onset SLE (cSLE). PLUTO, a Phase 2, placebo-controlled, double-blind trial (114055; NCT01649765), was the first…
Abstract Number: 2566 • 2019 ACR/ARP Annual Meeting
Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE
Dale Seguin¹, Christine Peschken ², Casandra Dolovich ¹, Ruby Grymonpre ¹, Phil St. John ¹ and Annaliese Tisseverasinghe ¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, Canada
Background/Purpose: Polypharmacy, typically defined as ≥ 5 medications (meds), is a strong risk factor for adverse clinical outcomes, including delirium, falls, hospitalization, and death, especially…
Abstract Number: 2567 • 2019 ACR/ARP Annual Meeting
Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates
Tatiana Pedrosa ¹, Sandra G. Pasoto ¹, Emily Yuki², Nadia Aikawa ¹, Eduardo Borba ¹, Julio Ferreira Filho ¹, Pedro Carricondo ³, Caio Zanetti ¹, Paola Conde ¹, Nicole Fontoura ¹, Paschoalina Romano ⁴, Valdemir Carvalho ⁵, Clovis Silva ⁶ and Eloisa Bonfa ⁷, ¹Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., São Paulo, Brazil, ³Ophtalmology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ⁴Division of Central Laboratory, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ⁵Fleury Group, Sao Paulo, Brazil, Sao Paulo, Brazil, ⁶Pediatric Rheumatology Unit, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Hydroxychloroquine (HCQ) is the most well established therapy for SLE, as it provides several beneficial properties, such as favorable effects on lipid profile, reduced…
Abstract Number: 2568 • 2019 ACR/ARP Annual Meeting
Iguratimod Is an Alternative Option for Refractory Lupus Nephritis: A Preliminary Observational Study
Qingran Yan¹, Chunde Bao ², Yuening Kang ¹, Qiong Fu ¹ and Ran Wang ¹, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Despite significant advances in the management of patients with lupus nephritis (LN), a significant proportion of patients either do not respond to first-line immunosuppressive…
Abstract Number: 2569 • 2019 ACR/ARP Annual Meeting
Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review
Gemma Cramarossa¹, Janet Pope ² and Matthew Turk ³, ¹Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada, ²Western University, London, ON, Canada, ³University of Western Ontario, London, ON, Canada
Background/Purpose: The purpose of this systematic review was to identify existing guidelines for antimalarial prescribing and monitoring in rheumatic diseases, specifically for hydroxychloroquine, and how…
Abstract Number: 2570 • 2019 ACR/ARP Annual Meeting
Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis
Amira El Gerby ¹, Abeer Abdelati ², Hanaa Donia ³ and Nouran Eshak⁴, ¹Rheumatology Department, Faculty of Medicine, Alexandria University, Egypt, Alexandria, Egypt, ²alexandria university, alexandria, Egypt, ³Clnical and Chemical Pathology Department, Faculty of Medicine, ALexandria University, Alexandria, Egypt, ⁴Rheumatology Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Lubbock, TX
Background/Purpose: Proliferative lupus nephritis (LN) is one of the most common and serious manifestations of SLE and is a major cause of morbidity. A search…
Abstract Number: 2571 • 2019 ACR/ARP Annual Meeting
Early Improvement in SLEDAI-2K Responder Index-50 Predicts SRI-4 Response in a Randomized Placebo-Controlled Trial of Ustekinumab (UST) in Systemic Lupus Erythematosus
Zahi Touma¹, Dafna Gladman ², Shawn Rose ³, Kaiyin Fei ³, Yun Gregan ³, Robert Gordon ³, Kim Hung Lo ³ and Murray Urowitz ¹, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: While traditional Systemic Lupus Erythematosus (SLE) Disease Activity Index 2000 (SLEDAI-2K) scoring assesses complete SLE response for individual disease manifestations, the SLEDAI-2K Responder Index-50…
Abstract Number: 2572 • 2019 ACR/ARP Annual Meeting
Efficacy Analysis of Patients with Systemic Lupus Erythematosus Treated with Belimumab or Placebo Plus Standard Therapy in Phase 3 Trials by Baseline Levels of BLyS mRNA and Type 1 Interferon Inducible Gene Signature Status
Angela R Jones-Leone¹, Shaun Flint ², Roger Abramino Levy ³, David Roth ⁴, Robert Henderson ², Christel Wilkinson ², Beulah Ji ⁵ and Damon L Bass ³, ¹GlaxoSmithKline, Upper Providence, ²GlaxoSmithKline, Stevenage, United Kingdom, ³GlaxoSmithKline, Collegeville, PA, ⁴GSK, Collegeville, PA, ⁵GSK, Uxbridge, Middlesex, United Kingdom
Background/Purpose: Belimumab (BEL) is a B-lymphocyte stimulator (BLyS) inhibitor approved as an add-on to standard of care (SoC) for patients with autoantibody-positive SLE with active…
Abstract Number: 2573 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: Comparison of Whole Blood and Serum Levels
Benoit Blanchet ¹, Jallouli Moez ², Marie Allard ³, veronique le guern ⁴, Jean-Charles Piette ⁵, Noémie Jourde-Chiche ⁶ and Nathalie Costedoat-Chalumeau⁷, ¹Cochin, Paris, France, ²sfax, SFAX, Tunisia, ³Hôpital Bichat Claude-Bernard, Paris, France, ⁴APHP, paris, France, ⁵Hôpital Pitié-Salpêtrière, Paris, France, ⁶APHM, Marseille, Marseille, France, ⁷Cochin University Hospital, Paris, France
Background/Purpose: Hydroxychloroquine (HCQ) levels can be measured in whole blood as well as in serum but both methods have never been compared. Cut offs for…
Abstract Number: 2574 • 2019 ACR/ARP Annual Meeting
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of BIIB059, a Monoclonal Antibody Targeting BDCA2 Following Administration of Subcutaneous Single Doses in Japanese Healthy Volunters
Cristina Musselli¹, Francois Gaudreault ¹, Naik Himanshu ¹, Hua Carroll ¹, Ankur Sharma ¹, Xiaobi Huang ¹ and Nathalie Franchimont ¹, ¹Biogen, Cambridge, MA
Background/Purpose: Background: BDCA2 is a plasmacytoid dendritic cell (pDC)-specific receptor that, when ligated inhibits the production of inflammatory mediators and Type I Interferon (INF), a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].